When a 20-something who received the Moderna vaccine showed symptoms of thrombosis, the local quarantine authorities requested a test to check whether the reaction was abnormal, but the Korea Centers for Disease Control and Prevention did not accept it.
According to the media coverage today (10th), a woman in her 20s living in Jeju received the Moderna vaccine at a consignment medical institution in the province on the 26th of last month, and on the 31st of the same month, five days later, she underwent surgery at a general hospital in Jeju with symptoms of thrombosis. received.
Jeju Island's quarantine authorities, who received a report of a severe adverse reaction to Mr. A, requested a thrombocytopenic thrombosis (TTS) test to the Korea Centers for Disease Control and Prevention to check if it was an adverse reaction to vaccination, but the Korea Centers for Disease Control and Prevention did not accept the request, saying Moderna was not subject to the test. .
Thrombocytopenic thrombosis is a very rare side effect after AstraZeneca (AZ) or Janssen vaccination, and it is known to occur mainly in young women.
Based on the fact that the World Health Organization (WHO) does not recognize thrombosis as a modern or vaccine side effect, the Korea Centers for Disease Control and Prevention is only conducting TTS testing when suspicious symptoms appear after AZ or Janssen vaccination.
The test request criteria are: ▲ TTS-suspected symptoms occur within 4 to 28 days after adenovector vaccine (AZ Janssen) inoculation ▲ Platelet count less than 150,000/μl ▲ D-dimer test level that can detect thrombosis rises ▲ If a blood clot is confirmed by imaging tests, etc.
It is known that Mr. A met all the other criteria except for the type of vaccine.
In response, Jeju Island authorities determined that testing was necessary based on the opinions of epidemiological investigators (medical personnel), etc.
However, it is known that the Korea Centers for Disease Control and Prevention (KCDC) did not accept the test request, saying that it was determined that the test was not necessary as a result of the review of the advisory group consisting of thrombosis experts.
Afterwards, while the Jeju-do authorities were looking for a way to request a test, Mr. A, who was receiving treatment at the hospital, finally died on the 7th.
Whether Mr. A's death is related to vaccination will be evaluated by the Korea Centers for Disease Control and Prevention.
However, since Mr. A has already died, it has become more difficult to determine causality.
In addition, it is known that the Korea Centers for Disease Control and Prevention has previously received TTS test samples for Pfizer adverse reactions, which are mRNA (messenger ribonucleic acid) like Moderna.
The matter has also been forwarded to the Korean Medical Association, and Jeju Island itself is said to be contemplating a response plan.
As of 00:00 yesterday (9th), there have been 128,612 cases of suspected adverse reactions reported since February 26, when the COVID-19 vaccine was started in Korea.
The reporting rate of adverse reactions relative to the number of vaccinations by vaccine was 0.68% for AZ, 0.67% for Janssen, 0.5% for Moderna, and 0.28% for Pfizer.
The cumulative number of reported deaths is 448, and when including deaths (191 people) who were reported first due to other symptoms and then died (191 people), the death toll was 639 (Pfizer 372, AZ 257, Janssen 9, Moderna 1).